Publication date: Sep 05, 2019
This post was originally published on this site Using smartphones and smartwatches to monitor disease course via the FLOODLIGHT app leads to high adherence and satisfaction among patients with multiple sclerosis (MS), results from a pilot study show. The research, -Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study,” was published in the Journal of Medical Internet Research. The test battery included active tests performed daily, weekly, every two weeks, or on demand for 24 weeks, and passive monitoring, which analyzed sensor-based gait and mobility. Adherence to both active tests and passive monitoring for the 24 weeks was good, and remained stable over time after week six. Data showed that 70% of participants completed all active tests, 75% did all active tests except the 2MWT, and 79% had data collected via smartphone- or smartwatch-based passive monitoring. FLOODLIGHT tests are being assessed in long-term studies with larger patient groups in the CONSONANCE Phase 3b trial of Ocrevus (ocrelizumab, by Roche-owned Genentech) in people with progressive MS (NCT03523858; still enrolling, contact information is here), and in a global study open to all MS patients with a mobile device, called FLOODLIGHT Open. The post Floodlight App Gets Positive Ratings, Shows Good Continuous Use in Pilot Study appeared first on Multiple Sclerosis News Today.
- Internet-based Physical Activity Promotion and Exercise Prescription for People With Multiple Sclerosis